- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01834898
Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery
Phase 4 Study, Open, Observational, to Evaluate the Safety and Tolerability of Hydrochloride Controlled-release Oxycodone in Moderate and Severe Postoperative Pain in Oncologic Head and Neck Surgery.
Study Overview
Status
Intervention / Treatment
Detailed Description
Phase IV clinical trial, observational, prospective, open approved by the Research Ethics Committee of the National Cancer Institute José Alencar Gomes da Silva - INCA, Brazil (no. 10/2010). The Instrument of Consent is signed by all patients.
Eighty-three patients will be included. Ages between 18 and 70 years both genders, 2 and 3 American Society of Anesthesiologists physical status, which present moderate to severe pain source postoperative surgical oncology, head and neck, medium and large, elective, non-emergency, able to swallow tablets whole (not chewed, broken or crushed) in the immediate postoperative period after recovery of cognitive functions. Will be excluded pregnant or breastfeeding, allergic to oxycodone and other opioids, gastrectomized or colostomized, asthmatics with severe organ dysfunction, with a history or suspected paralytic ileus, or a history psychiatric disorders, severe respiratory depression, patients who are receiving opioid analgesics in baseline, history of abuse of alcohol and illicit drugs, patients who present in plasma glutamic oxaloacetic transaminase above 48 U / l (men) and 40 U / I (women) and / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U / I (women) and patients who present plasma creatinine above 1.7 mg / dl and / or urea above 65 mg / dl. All patients will be assessed preoperatively seven to one day before surgery (visit 1) when will the signed consent form, proceeded to pre-anesthetic evaluation and blood will be collected for laboratory tests: complete blood count, β-human chorionic gonadotropin(women), glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, creatinine and urea.
In the immediate postoperative period (visit 2), the pain will be assessed by verbal numeric scale (VNS) and when pain is moderate to severe (≥ 4 EVN) and the patient is lucid and able to swallow, will start orally controlled-release oxycodone (Oxycontin, Zodiac Pharmaceuticals, Brazil) at a dose of 20 mg (tablets whole without crushing or division), administered by the investigator. Every 12 hours and a subsequent period of 48 hours after the first dose of oxycodone controlled-release, the pain will be evaluated again, and the occurrence and intensity of adverse events (visits 3, 4, 5 and 6 respectively 12 , 24, 36 and 48 hours after the first dose of oxycodone). The doses of controlled-release oxycodone will be standardized as follows: on the first day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours.
The rescue medication will be used non opioids analgesics as paracetamol, dipyrone, diclofenac or tenoxicam, only after the first administration of controlled-release oxycodone postoperatively. During the visits described above will be annotated to rescue analgesia and its frequency, should it ever be used between doses of oxycodone.
Between post-operative 7 and 13 days will be held the visit 7, which will be evaluated pain intensity (EVN), the occurrence and severity of adverse effects, and the investigator's opinion about treatment. Finally, the patient's blood will be collected to perform the same tests listed at visit 1, except β-human chorionic gonadotropin (women), and the study was terminated.
Sample Size and Statistical Analysis
When considering the occurrence of nausea of 25% as a safety parameter, assessed by literature data, the number of patients required will be 72. Taking into consideration a dropout of about 20% will require 86 patients in total (to an accuracy of 10%, around the percentage confidence interval (CI) 95%). The study of normal age variable will be conducted with the test Kolmogorov - Smirnov. The Friedman test is used to compare medians of pain intensity from visit 2 to visit 7. The Dunn test will be used for post-hoc comparisons (between two) of median pain intensity (p <0.001 - significant). The McNemar test for pairwise comparisons of proportions will be employed for comparisons of adverse events (visits 4, 5, 6 and 7 with respect to visit 3) (p <0.05 = significant). The remaining data will be presented by frequency.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 20230-130
- Instituto Nacional de Câncer José Alencar Gomes da Silva
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients on postoperative head and neck oncologic surgery
- 2 and 3 American Society of Anesthesiologists physical status
- moderate to severe postoperative pain
- elective surgery
- able to swallow tablets whole (not chewed, broken or crushed) in the immediate postoperative period after recovery of cognitive functions.
Exclusion Criteria:
- pregnant or breastfeeding
- allergic to oxycodone and other opioids
- gastrectomized or colostomized
- asthmatics with severe organ dysfunction
- history or suspected paralytic ileus
- history psychiatric disorders
- severe respiratory depression
- patients who are receiving opioid analgesics in baseline
- history of abuse of alcohol and illicit drugs
- plasma glutamic oxaloacetic transaminase above 48 U / l (men) and 40 U / I (women) and / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U / I (women)
- plasma creatinine above 1.7 mg / dl and / or urea above 65 mg / dl
- emergency surgery
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Controlled-release oxycodone
Controlled-released oxycodone.
First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
|
Controlled-release oxycodone.
First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with nausea
Time Frame: 48 hours post dose
|
number of participants with nausea 48 hours after first dose of controlled-released oxycodone
|
48 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity
Time Frame: 48 hours post dose
|
pain intensity by numerical scale 48 hours after the first dose of controlled released oxycodone
|
48 hours post dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of quality of postoperative analgesia
Time Frame: At the seventh postoperative day
|
Investigator's opinion about treatment
|
At the seventh postoperative day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ismar L Cavalcanti, MD PhD, Instituto Nacional de Câncer Brazil
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Vomiting
- Nausea
- Pain, Postoperative
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Oxycodone
Other Study ID Numbers
- INCA 10/2010
- INCABrazil (Instituto Nacional de Câncer)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Controlled-release oxycodone
-
Purdue Pharma LPCompletedLow Back PainUnited States, Poland, Czech Republic, Italy
-
Purdue Pharma LPCompleted
-
Purdue Pharma LPCompletedOpioid AnalgesiaUnited States, Australia, Finland, New Zealand
-
Purdue Pharma LPCompleted
-
Purdue Pharma LPCompletedPainUnited States, Israel, Spain, United Kingdom, Greece, Hungary, New Zealand, Romania
-
University Health Network, TorontoCanadian Society of Hospital PharmacistsWithdrawn
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Fujian Cancer HospitalWithdrawn
-
MallinckrodtCompleted